124 related articles for article (PubMed ID: 20101834)
1. [Implantable defibrillator--with focus on primary prevention. Detailed patient information about risks and benefits is required].
Jensen SM; Kesek M
Lakartidningen; 2009 Nov 25-Dec 1; 106(48):3236, 3238-41. PubMed ID: 20101834
[No Abstract] [Full Text] [Related]
2. [The benefits of the implantable cardioverter-defibrillator in comparisons with anti-arrhythmia agents in patients surviving malignant ventricular tachyarrhythmias: a subanalysis of the AVID study by varying degrees of left ventricular dysfunction. Antiarrhythmic versus Implantable Defibrillators].
Occhetta E
Ital Heart J Suppl; 2000 Apr; 1(4):577-8. PubMed ID: 10832149
[No Abstract] [Full Text] [Related]
3. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator.
Prystowsky EN
Rev Cardiovasc Med; 2001; 2(4):197-205. PubMed ID: 12439369
[TBL] [Abstract][Full Text] [Related]
4. Long term management of the survivor of ventricular fibrillation or sustained ventricular tachycardia.
Connolly SJ; Krahn A; Klein G
Can J Cardiol; 2000 Jun; 16 Suppl C():20C-2C. PubMed ID: 10887273
[No Abstract] [Full Text] [Related]
5. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia in patients with an implantable defibrillator warrants catheter ablation.
Kuck KH
Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):713-20; discussion 720. PubMed ID: 20009082
[No Abstract] [Full Text] [Related]
6. [Primary prophylactic treatment with implantable defibrillator in high risk patients].
Møller M; Haghfelt T
Ugeskr Laeger; 2000 Jul; 162(31):4160-1. PubMed ID: 10962922
[No Abstract] [Full Text] [Related]
7. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy.
Patel C; Yan GX; Kocovic D; Kowey PR
Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):705-11; discussion 712. PubMed ID: 20009081
[No Abstract] [Full Text] [Related]
8. [Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone].
Della Bella P
Ital Heart J Suppl; 2000 Aug; 1(8):1070-1. PubMed ID: 10993020
[No Abstract] [Full Text] [Related]
9. Do traditional VT zones improve outcome in primary prevention ICD patients?
Duncan E; Thomas G; Johns N; Pfeffer C; Appanna G; Shah N; Hunter R; Finlay M; Schilling RJ; Sporton S
Pacing Clin Electrophysiol; 2010 Nov; 33(11):1353-8. PubMed ID: 20727095
[TBL] [Abstract][Full Text] [Related]
10. Application of the main implantable cardioverter-defibrillator trials and the 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
Proclemer A; Ghidina M
J Cardiovasc Med (Hagerstown); 2007 May; 8(5):320-3. PubMed ID: 17443096
[No Abstract] [Full Text] [Related]
11. Ventricular tachycardia and ventricular fibrillation.
Srivathsan K; Ng DW; Mookadam F
Expert Rev Cardiovasc Ther; 2009 Jul; 7(7):801-9. PubMed ID: 19589116
[TBL] [Abstract][Full Text] [Related]
12. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
[TBL] [Abstract][Full Text] [Related]
14. Food for afterthought: reflections from 2 implantable cardioverter defibrillator trials.
Rahimtoola SH
Arch Intern Med; 2004 Sep; 164(17):1835-9. PubMed ID: 15451756
[No Abstract] [Full Text] [Related]
15. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
[TBL] [Abstract][Full Text] [Related]
16. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
Wilkoff BL;
Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
[TBL] [Abstract][Full Text] [Related]
17. Implantable cardioverter defibrillator therapy: ten years experience in a medical center.
Chen TE; Wang CC; Chang SH; Yeh SJ; Wu D
Chang Gung Med J; 2008; 31(1):81-90. PubMed ID: 18419057
[TBL] [Abstract][Full Text] [Related]
18. Learning more about indications for implantable cardioverter-defibrillators.
Myerburg RJ; Castellanos A
J Am Coll Cardiol; 1999 Oct; 34(4):1096-8. PubMed ID: 10520796
[No Abstract] [Full Text] [Related]
19. Implantable cardioverter-defibrillator: present and future indications.
Block M; Scheld H; Breithardt G
Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():141-7. PubMed ID: 8734176
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
